{
    "info": {
        "nct_id": "NCT05256641",
        "official_title": "Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse",
        "inclusion_criteria": "* Ages 18-70 years\n* One of the following:\n\n  * Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:\n\n    * High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc\n    * Large B-cell lymphoma with a history of secondary CNS involvement\n    * Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia\n    * High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis\n  * Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Requirements for post-ASCT and post-alloHCT participants:\n\n  * Disease status of partial response (PR) or complete response (CR) prior to transplantation\n  * Receive reduced-intensity conditioning regimen\n  * Enrollment no later than day +90\n* Requirements for post-CAR T-cell therapy participants:\n\n  * Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months\n  * Enrollment no later than day +104\n* Ability to give full informed consent\n* Female subjects who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib\n* Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty\n* Absolute neutrophil count (ANC) > 500/uL (microliters)\n* Platelets > 50,000/uL independent of transfusions\n* Hemoglobin > 8 g/dL independent of transfusions\n* Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)\n* Total bilirubin =< 1.5 x ULN, unless directly attributable to Gilbert's syndrome\n* Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =< 1.8 mg/dL\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
        "exclusion_criteria": "* Cord blood as donor source in alloHCT\n* New York Heart Association Class III or IV\n* Left ventricular ejection fraction < 50%\n* Estimated glomerular filtration rate < 30 mL/min\n* Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication\n* Acute or chronic graft-versus-host disease (GvHD) >= stage 3 at time of enrollment\n* Received packed red blood cells (pRBC) transfusion within the past 2 weeks\n* Received platelet transfusion within the past 1 week\n* Active invasive fungal infection\n* Active bacterial or viral infection until resolution of the infection\n* History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)\n* Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug\n* Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug\n* Refractory nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment\n* Received a live virus vaccination within 28 days of first dose of study drug\n* Known history of infection with human immunodeficiency virus (HIV)\n* History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)\n* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists\n* Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited\n* Breastfeeding or pregnant\n* Concurrent participation in another therapeutic clinical trial",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Disease status of partial response (PR) or complete response (CR) prior to transplantation",
            "criterions": [
                {
                    "exact_snippets": "Disease status of partial response (PR) or complete response (CR) prior to transplantation",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "partial response",
                                "complete response"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to transplantation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =< 1.8 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR)",
                    "criterion": "creatinine clearance (Cockcroft-Gault GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine (Cr) =< 1.8 mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.8,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Large B-cell lymphoma with a history of secondary CNS involvement",
            "criterions": [
                {
                    "exact_snippets": "Large B-cell lymphoma",
                    "criterion": "Large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of secondary CNS involvement",
                    "criterion": "secondary CNS involvement",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requirements for post-ASCT and post-alloHCT participants:",
            "criterions": [
                {
                    "exact_snippets": "post-ASCT",
                    "criterion": "autologous stem cell transplant (ASCT) status",
                    "requirements": [
                        {
                            "requirement_type": "history of ASCT",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "post-alloHCT",
                    "criterion": "allogeneic hematopoietic cell transplant (alloHCT) status",
                    "requirements": [
                        {
                            "requirement_type": "history of alloHCT",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x ULN, unless directly attributable to Gilbert's syndrome",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x ULN, unless directly attributable to Gilbert's syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless directly attributable to Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:",
            "criterions": [
                {
                    "exact_snippets": "Patients undergoing autologous stem cell transplantation (ASCT)",
                    "criterion": "autologous stem cell transplantation (ASCT)",
                    "requirements": [
                        {
                            "requirement_type": "undergoing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product",
                    "criterion": "FDA-approved chimeric antigen receptor (CAR) T-cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "undergoing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Enrollment no later than day +104",
            "criterions": [
                {
                    "exact_snippets": "Enrollment no later than day +104",
                    "criterion": "enrollment date",
                    "requirements": [
                        {
                            "requirement_type": "date relative to reference",
                            "expected_value": {
                                "operator": "<=",
                                "value": 104,
                                "unit": "days from reference point (e.g., transplant or diagnosis)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc",
            "criterions": [
                {
                    "exact_snippets": "High grade B-cell lymphoma (double or triple hit)",
                    "criterion": "B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "high"
                        },
                        {
                            "requirement_type": "hit status",
                            "expected_value": [
                                "double hit",
                                "triple hit"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "rearrangements in bcl-2 and/or bcl-6",
                    "criterion": "bcl-2 and/or bcl-6 gene rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "rearrangement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rearrangement in myc",
                    "criterion": "myc gene rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "rearrangement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to participate in all required evaluations and procedures in this study protocol",
                    "criterion": "willingness and ability to participate in study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "swallowing capsules and tablets without difficulty",
                    "criterion": "ability to swallow capsules and tablets",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "difficulty",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ages 18-70 years",
            "criterions": [
                {
                    "exact_snippets": "Ages 18-70 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 70,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requirements for post-CAR T-cell therapy participants:",
            "criterions": [
                {
                    "exact_snippets": "post-CAR T-cell therapy participants",
                    "criterion": "CAR T-cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": "post-CAR T-cell therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) > 500/uL (microliters)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) > 500/uL (microliters)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 8 g/dL independent of transfusions",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "independent of transfusions",
                    "criterion": "hemoglobin level independence from transfusions",
                    "requirements": [
                        {
                            "requirement_type": "independence from transfusions",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT)",
                    "criterion": "allogeneic hematopoietic cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "undergoing procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "large B-cell lymphoma",
                    "criterion": "large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Enrollment no later than day +90",
            "criterions": [
                {
                    "exact_snippets": "Enrollment no later than day +90",
                    "criterion": "enrollment date",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 70 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 70 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* One of the following:",
            "criterions": [
                {
                    "exact_snippets": "One of the following",
                    "criterion": "alternative criteria group",
                    "requirements": [
                        {
                            "requirement_type": "selection",
                            "expected_value": "at least one of the following criteria must be met"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets > 50,000/uL independent of transfusions",
            "criterions": [
                {
                    "exact_snippets": "Platelets > 50,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50000,
                                "unit": "uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "independent of transfusions",
                    "criterion": "platelet count independence from transfusions",
                    "requirements": [
                        {
                            "requirement_type": "independence from transfusions",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib",
            "criterions": [
                {
                    "exact_snippets": "Female subjects who are sexually active and can bear children",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": "while on the study and for 2 days after the last dose of acalabrutinib"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months",
            "criterions": [
                {
                    "exact_snippets": "Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "response category",
                            "expected_value": [
                                "PR",
                                "CR"
                            ]
                        },
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "positron emission tomography (PET)-computed tomography (CT)"
                            ]
                        },
                        {
                            "requirement_type": "post-therapy",
                            "expected_value": "post-CAR T-cell therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum aspartate aminotransferase (AST) ... =< 3 x upper limit of normal (ULN)",
                    "criterion": "serum aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to give full informed consent",
            "criterions": [
                {
                    "exact_snippets": "Ability to give full informed consent",
                    "criterion": "informed consent ability",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receive reduced-intensity conditioning regimen",
            "criterions": [
                {
                    "exact_snippets": "Receive reduced-intensity conditioning regimen",
                    "criterion": "conditioning regimen",
                    "requirements": [
                        {
                            "requirement_type": "intensity",
                            "expected_value": "reduced"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis",
            "criterions": [
                {
                    "exact_snippets": "High risk international prognostic index (IPI) score 4 or 5",
                    "criterion": "international prognostic index (IPI) score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at diagnosis or prior to CAR T-cell leukapheresis",
                    "criterion": "timing of IPI score assessment",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at diagnosis",
                                "prior to CAR T-cell leukapheresis"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug",
                    "criterion": "receipt of investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication",
            "criterions": [
                {
                    "exact_snippets": "Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors",
                    "criterion": "concurrent long-term use of strong CYP3A4 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to replace with equivalent medication",
                    "criterion": "ability to replace strong CYP3A4 inhibitor with equivalent medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received packed red blood cells (pRBC) transfusion within the past 2 weeks",
            "criterions": [
                {
                    "exact_snippets": "Received packed red blood cells (pRBC) transfusion within the past 2 weeks",
                    "criterion": "packed red blood cells (pRBC) transfusion",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active bacterial or viral infection until resolution of the infection",
            "criterions": [
                {
                    "exact_snippets": "Active bacterial or viral infection until resolution of the infection",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Active bacterial or viral infection until resolution of the infection",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cord blood as donor source in alloHCT",
            "criterions": [
                {
                    "exact_snippets": "Cord blood as donor source in alloHCT",
                    "criterion": "donor source for allogeneic hematopoietic cell transplantation (alloHCT)",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "cord blood"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Breastfeeding or pregnant",
            "criterions": [
                {
                    "exact_snippets": "Breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received platelet transfusion within the past 1 week",
            "criterions": [
                {
                    "exact_snippets": "Received platelet transfusion within the past 1 week",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists",
            "criterions": [
                {
                    "exact_snippets": "Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists",
                    "criterion": "anticoagulation with warfarin or equivalent vitamin K antagonists",
                    "requirements": [
                        {
                            "requirement_type": "use or requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active invasive fungal infection",
            "criterions": [
                {
                    "exact_snippets": "Active invasive fungal infection",
                    "criterion": "invasive fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)",
            "criterions": [
                {
                    "exact_snippets": "History of ... confirmed progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_status",
                            "expected_value": "confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing confirmed progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirements": [
                        {
                            "requirement_type": "current_status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "confirmation_status",
                            "expected_value": "confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent participation in another therapeutic clinical trial",
            "criterions": [
                {
                    "exact_snippets": "Concurrent participation in another therapeutic clinical trial",
                    "criterion": "participation in another therapeutic clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "concurrent participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated glomerular filtration rate < 30 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Estimated glomerular filtration rate < 30 mL/min",
                    "criterion": "estimated glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of infection with human immunodeficiency virus (HIV)",
            "criterions": [
                {
                    "exact_snippets": "Known history of infection with human immunodeficiency virus (HIV)",
                    "criterion": "infection with human immunodeficiency virus (HIV)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association Class III or IV",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Class III or IV",
                    "criterion": "New York Heart Association (NYHA) heart failure class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)",
            "criterions": [
                {
                    "exact_snippets": "History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemophilia",
                    "criterion": "hemophilia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "von Willebrand disease",
                    "criterion": "von Willebrand disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure within 30 days before the first dose of study drug",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug",
                    "criterion": "recovery from surgical toxicity and/or complications",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited",
            "criterions": [
                {
                    "exact_snippets": "Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer",
                    "criterion": "treatment with strong CYP3A inhibitor or inducer",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "The use of strong CYP3A inhibitors within 1 week ... is prohibited",
                    "criterion": "use of strong CYP3A inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "strong CYP3A inducers within 3 weeks ... is prohibited",
                    "criterion": "use of strong CYP3A inducers",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Refractory nausea and vomiting",
                    "criterion": "nausea and vomiting",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to swallow the formulated product",
                    "criterion": "ability to swallow formulated product",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic gastrointestinal disease",
                    "criterion": "chronic gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastric restrictions",
                    "criterion": "gastric restrictions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bariatric surgery such as gastric bypass",
                    "criterion": "bariatric surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete bowel obstruction",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment",
                    "criterion": "significant bowel resection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on absorption, distribution, metabolism, or excretion of study treatment",
                            "expected_value": "precludes adequate function"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live virus vaccination within 28 days of first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Received a live virus vaccination within 28 days of first dose of study drug",
                    "criterion": "live virus vaccination",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "temporal_relation",
                            "expected_value": "prior to first dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute or chronic graft-versus-host disease (GvHD) >= stage 3 at time of enrollment",
            "criterions": [
                {
                    "exact_snippets": "Acute or chronic graft-versus-host disease (GvHD) >= stage 3 at time of enrollment",
                    "criterion": "graft-versus-host disease (GvHD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "stage"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction < 50%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction < 50%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia",
            "criterions": [
                {
                    "exact_snippets": "Histologic transformation of indolent lymphoma to large B-cell lymphoma",
                    "criterion": "histologic transformation to large B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "indolent lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia",
                    "criterion": "indolent lymphoma subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "marginal zone lymphoma",
                                "follicular lymphoma",
                                "chronic lymphocytic leukemia (CLL)",
                                "small lymphocytic lymphoma (SLL)",
                                "lymphoplasmacytic leukemia",
                                "Waldenstrom macroglobulinemia"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}